The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation
Open accessAbstract
BACKGROUND: Effective and enforceable national regulations describing the manufacture and (re)packaging, export and import, distribution and storage, supply and sale, information and pharmaco-vigilance of medicines are required to consistently ensure optimal patient benefit. Expansion of pharmaceutical industries in many countries with advancement in transport technologies facilitated not only trade of genuine pharmaceutical products but also the circulation of poor quality medicines across the globe. In Ethiopia, even though "The Pharmacists and Druggists Proclamation No 43/1942" was used to regulate both the professions and the facilities where they were practiced, comprehensive regulation of the pharmaceutical market was introduced in 1964 by a regulation called "Pharmacy Regulation No. 288/ 1964". This legislation formed the legal basis for official establishment of drug regulation in the history of Ethiopia, enabling the regulation of the practice of pharmacists, druggists and pharmacy technicians; manufacturing, distribution, and sale of medicines. In June 1999, a new regulation called the "Drug Administration and Control Proclamation No. 176/1999" repealed most parts of the regulation 288/1964. The law established an independent Drug Administration and Control Authority (DACA) with further mandate of setting standards of competence for licensing institutions/facilities. DACA was re-structured as Food, Medicine and Health Care Administration and Control Authority (EFMHACA) of Ethiopia by the "Proclamation No. 661/2009" in 2010 bearing additional responsibilities like regulation of food, health care personnel and settings. The mere existence of this legal framework does not guarantee complete absence of illegal, substandard and falsified products as well as illegal establishments in the pharmaceutical chain. Therefore, the objective of the research is to assess the pharmaceutical regulatory system in Ethiopia and to reveal possible reasons for deficiencies in the pharmaceutical chain. METHODS: An archival review, an in-depth interview of key informants and an institutions-based cross-sectional survey study were conducted during March to April 2013. The comprehensiveness of the pharmaceutical law to protect public health relative to three selected African countries (South Africa, Tanzania and Uganda) and European Union, and implementation was assessed. RESULTS: The study revealed that Ethiopia does have a written national drug policy upon which the Medicines Regulatory Proclamation 661/2009 is based. According to this proclamation, the Ethiopian The Food, Medicines and Healthcare Administration and Control Authority is mandated to execute the regulatory activities as per the council of ministers regulation 189/2010. The legal framework for pharmaceutical regulation of Ethiopia was founded to fulfill all the medicines regulatory functions potentially enabling to combat illegal, substandard and falsified medicines and illegal establishments. Moreover, all the key informants witnessed that the government is commited and proclamation 661/2009 is comprehensive, but they stressed the compelling need of regulatory tools for effective implementation. From the institution-based cross-sectional study, it was revealed that there exist illegal sources formedicine in the pharmaceutical market. The main reasons for their existence were regulatory factors including weak regulatory enforcement (64.5%), lack of informal market control (60.8%), weak port control (50.0%), and poor cooperation between executive bodies (39.6%); and resource constraint (27.8%), which is an institutional factor. CONCLUSIONS: From legislative point of view, the medicines regulatory framework in Ethiopia fulfils all regulatory functions required for effective medicines regulation. However, the existence of the legislation by its own is not a guarantee to prevent the existence of unauthorized/illegal medicine sources since this requires effective implementation of the legislation, which is in fact affected by the governments political commitment, resource and intergovernmental cooperation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Ethiopia, many CDROs take advantage of regulatory gaps and lack of legal repercussion to receive medicines from illegal cross-border markets.
“For similar reason, in Ethiopia, many CDROs have been also taking advantage of the regulatory gaps and lack of legal repercussion to receive medicines from illegal market across borders [60].”
From No prescription? No problem: drivers of non-prescribed sale of antibiotics among community drug retail outlets in low and middle income countries: a systematic review of qualitative studies (2021) · cites this paper as [60]
The Results (Product assessment and registration; page unavailable) identify retail outlets as primary destinations for illegal medicines and link smuggling to regulatory gaps, weak border control, and inadequate enforcement. They do not establish that many CDROs deliberately exploit those weaknesses or that a lack of legal repercussions specifically enables them to obtain medicines from cross-border markets. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Qualitative and Mixed Methods Provide Unique Contributions to Outcomes Research
Curry, L. A., Nembhard, I. M., & Bradley, E. H. (2009) · Circulation · doi:10.1161/circulationaha.107.742775 · Cited by 1,175
Federal Democratic Republic of Ethiopia
Kefale, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-42088-8_11 · Cited by 735
Regulating Medicines in Europe: Competition, Expertise and Public Health
Abraham, J. M., & Lewis, G. (2000) · Cited by 123
Drug Regulation and Control in Nigeria: the Challenge of Counterfeit Drugs
Erhun, W. O., Babalola, O. O., & O, M. O. (2013) · World health & population · doi:10.12927/whp..17597 · Cited by 113
Effective Drug Regulation: A Multicountry Study
Ratanawijitrasin, S., & Wondemagegnehu, E. (2002) · Cited by 92
Drug Benefits and Risks: International Textbook of Clinical Pharmacology
Santoso, B., van Boxtel, C. J., & Edwards, I. R. (2008) · Cited by 77
PRIVATE PHARMACY PRACTICE AND REGULATION
Stenson, B., Syhakhang, L., Lundborg, C. S., Eriksson, B., & Göran (2001) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462301107129 · Cited by 68
Suleman, S., Zeleke, G., Waktola, H. D., Mekonnen, Z., Duchateau, L., Levecke, B., Vercruysse, J., D’Hondt, M., Wynendaele, E., & Spiegeleer, B. M. J. D. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003345 · Cited by 55
Self-citationSubstandard and counterfeit medicines.
Rassool, G. H. (2004) · PubMed · Cited by 52
Registering New Drugs for Low-Income Countries: The African Challenge
Moran, M., Strub-Wourgaft, N., Guzman, J., Boulet, P., Wu, L., & Pecoul, B. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000411 · Cited by 44
The Regulation and Approval of New Drugs in China
Deng, R., & Kaitin, K. I. (2004) · Drug Information Journal · doi:10.1177/009286150403800105 · Cited by 39
Antimalarial Medicine Diversion: Stock-Outs and Other Public Health ProblemsPreprint
Bate, R., Hess, K., & Mooney, L. (2010) · SSRN Electronic Journal · Cited by 10
THE WORLD MEDICINES SITUATION 2011 GOOD GOVERNANCE FOR THE PHARMACEUTICAL SECTOR
Köhler, J. C. (2011) · TSpace (University of Toronto) · Cited by 8
Flagged first, then by citations
Research works printed but not linked: 4
- [4]Tobin JJ Walsh G Medical products regulatory affairs: Pharmaceuticals, Diagnostics, Medical Devices 2008 Weinheim Wiley-Blackwell
- [20]World Health Organization Practical guide for conducting review based on WHO Data collection tool for the review of drug regulatory system, Module 3: National regulatory authority 2008 Geneva; Switzerland
- [23]International Conference on Harmonization ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients 2000 Geneva, Switzerland
- [31]Mustafa T Assessment of pharmacy professionals' perception and experience towards non-conventional drug market: A pilot study on private pharmaceutical wholesales in Addis Ababa 2011 Ethiopia Addis Ababa University School of Pharmacy (Unpublished M.Sc. Thesis)
Cited by
Sorted by citations
Belachew, S. A., Hall, L., Erku, D. A., & Selvey, L. A. (2021) · BMC Public Health · doi:10.1186/s12889-021-11163-3 · Cited by 73
“For similar reason, in Ethiopia, many CDROs have been also taking advantage of the regulatory gaps and lack of legal repercussion to receive medicines from illegal market across borders [60].”
Background
Metadata
- Authors
- Suleman, S., Woliyi, A., Woldemichael, K., Tushune, K., Duchateau, L., Degroote, A., Vancauwenberghe, R., Bracke, N., & De Spiegeleer, B.
- Affiliations
- Jimma University (ET)
- Government of Ethiopia (ET)
- Ghent University (BE)
- Venue
- Ethiopian Journal of Health Sciences
- Publisher
- African Journals Online (AJOL)
- Published
- 2016-05-16
- Volume
- 26
- Issue
- 3
- Pages
- 259
- ISSN
- 1029-1857 (ISSN-L)
- PMC
- PMC4913194
- OpenAlex
- W2408265127
- Cited by
- 72
- References
- 13
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 7 · 2021: 17 · 2020: 6 · 2019: 1 · 2018: 6 · 2017: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Ethiopian Journal of Health Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Funders
- Jimma University
- Vlaamse Interuniversitaire Raad
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- drug regulation, Ethiopia, regulatory implementation, substandard and falsified medicines, pharmaceutical supply chain, national drug policy, regulatory capacity, South Africa, Tanzania, Uganda, European Union, public health protection
- MeSH terms
- Cross-Sectional Studies, Developing Countries, Drug and Narcotic Control, Drug Industry, Pharmaceutical Preparations, Ethiopia, Humans, Government Regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review